CN101396554A - 重组人干扰素γ在制备抗病毒药物中的应用 - Google Patents
重组人干扰素γ在制备抗病毒药物中的应用 Download PDFInfo
- Publication number
- CN101396554A CN101396554A CNA2007100463821A CN200710046382A CN101396554A CN 101396554 A CN101396554 A CN 101396554A CN A2007100463821 A CNA2007100463821 A CN A2007100463821A CN 200710046382 A CN200710046382 A CN 200710046382A CN 101396554 A CN101396554 A CN 101396554A
- Authority
- CN
- China
- Prior art keywords
- hsv
- recombinant human
- interferon gamma
- cell
- human interferon
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNA2007100463821A CN101396554A (zh) | 2007-09-25 | 2007-09-25 | 重组人干扰素γ在制备抗病毒药物中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNA2007100463821A CN101396554A (zh) | 2007-09-25 | 2007-09-25 | 重组人干扰素γ在制备抗病毒药物中的应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN101396554A true CN101396554A (zh) | 2009-04-01 |
Family
ID=40515554
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNA2007100463821A Pending CN101396554A (zh) | 2007-09-25 | 2007-09-25 | 重组人干扰素γ在制备抗病毒药物中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101396554A (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109819650A (zh) * | 2017-09-25 | 2019-05-28 | 春布里泽·格奥尔基·格奥尔基耶维奇 | 具有抗病毒和抗细菌活性的热稳定组合物及其用途 |
CN112089841A (zh) * | 2020-04-05 | 2020-12-18 | 徐静 | 用于治疗上皮组织病毒感染所致疾病的药物组合物 |
-
2007
- 2007-09-25 CN CNA2007100463821A patent/CN101396554A/zh active Pending
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109819650A (zh) * | 2017-09-25 | 2019-05-28 | 春布里泽·格奥尔基·格奥尔基耶维奇 | 具有抗病毒和抗细菌活性的热稳定组合物及其用途 |
CN112089841A (zh) * | 2020-04-05 | 2020-12-18 | 徐静 | 用于治疗上皮组织病毒感染所致疾病的药物组合物 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Antoine et al. | Intravaginal zinc oxide tetrapod nanoparticles as novel immunoprotective agents against genital herpes | |
Cohen et al. | Recent advances in varicella-zoster virus infection | |
Ike et al. | Immune response to herpes simplex virus infection and vaccine development | |
Pourchet et al. | CD8+ T-cell immune evasion enables oncolytic virus immunotherapy | |
CN102083457B (zh) | 天花dna疫苗及其引起免疫应答的抗原 | |
Milligan et al. | T-cell-mediated mechanisms involved in resolution of genital herpes simplex virus type 2 (HSV-2) infection of mice | |
CN113082049A (zh) | 碘化钾或含有碘化钾的组合物用于预防或治疗非洲猪瘟的新用途 | |
Huang et al. | Protective effects of recombinant human granulocyte macrophage colony stimulating factor on H1N1 influenza virus-induced pneumonia in mice | |
Misra et al. | Current updates on COVID-19 vaccines | |
Righi et al. | The cell-mediated immune response against Bovine alphaherpesvirus 1 (BoHV-1) infection and vaccination | |
KR20080048542A (ko) | 인간 유두종 바이러스에 저항하는 약제 제조를 위한노카르디아 루브라 세포벽 골격의 용도 | |
Liu et al. | Selective editing of herpes simplex virus 1 enables interferon induction and viral replication that destroy malignant cells | |
CN101396554A (zh) | 重组人干扰素γ在制备抗病毒药物中的应用 | |
CN104721839A (zh) | 一种预防单纯疱疹病毒ii型的疫苗 | |
Ghaemi et al. | Echinacea purpurea polysaccharide reduces the latency rate in herpes simplex virus type-1 infections | |
CN108619123A (zh) | Tenovin-1在制备防治人类疱疹病毒感染药物中的应用 | |
Frejborg et al. | Current landscape in antiviral drug development against herpes simplex virus infections | |
CN106344613A (zh) | 一种nk细胞原液在制备治疗皮肤病药物中的应用 | |
CN102166353B (zh) | 一种用于治疗人乳头瘤病毒感染引起的疾病的喷剂及制备 | |
CN106562970B (zh) | Gs-9620的用途 | |
CN102405057A (zh) | 用免疫刺激性Hiv Tat衍生物多肽治疗癌症 | |
Borase et al. | The Interplay of Genital Herpes with Cellular Processes: A Pathogenesis and Therapeutic Perspective | |
Murmu et al. | Efficacy and limitations of repurposed drugs and vaccines for COVID-19 | |
CN101686993B (zh) | 卡介菌多糖核酸提取物在制备治疗病毒性皮肤病的药物中的应用及其注射剂和制备方法 | |
Bilsborrow et al. | Chikungunya: an emerging rheumatological pandemic |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
ASS | Succession or assignment of patent right |
Owner name: SHANGHAI KAIMAO BIOLOGICAL MEDICINE CO., LTD. Free format text: FORMER OWNER: SHANGHAI CLONE BIOLOGY HIGH TECHNOLOGY LTD. Effective date: 20090410 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20090410 Address after: No. 1289, Yishan Road, Shanghai Applicant after: Shanghai Kayu bio Pharmaceutical Co., Ltd. Co-applicant after: Shanghai Fosun Pharmaceutical (Group) Limited by Share Ltd. Address before: No. 1289, Yishan Road, Shanghai Applicant before: Shanghai clone bio High Technology Co., Ltd. Co-applicant before: Shanghai Fosun Pharmaceutical (Group) Limited by Share Ltd. |
|
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication |
Open date: 20090401 |